AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 1.17
(0.0%)
SEK 1.17
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -476 Thousand SEK | 16.49% |
| 2022 | -570 Thousand SEK | 1.04% |
| 2021 | -576 Thousand SEK | -16.36% |
| 2020 | -495 Thousand SEK | 98.89% |
| 2019 | -44.78 Million SEK | -42966.35% |
| 2018 | -104 Thousand SEK | -111.88% |
| 2017 | 875.38 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -69 Thousand SEK | 36.7% |
| 2024 Q1 | -109 Thousand SEK | 0.91% |
| 2023 Q4 | -110 Thousand SEK | -0.92% |
| 2023 FY | -476 Thousand SEK | 16.49% |
| 2023 Q3 | -109 Thousand SEK | 12.8% |
| 2023 Q2 | -125 Thousand SEK | 5.3% |
| 2023 Q1 | -132 Thousand SEK | 2.94% |
| 2022 FY | -570 Thousand SEK | 1.04% |
| 2022 Q3 | -145 Thousand SEK | 0.0% |
| 2022 Q2 | -145 Thousand SEK | -0.69% |
| 2022 Q1 | -144 Thousand SEK | 0.69% |
| 2022 Q4 | -136 Thousand SEK | 6.21% |
| 2021 Q2 | -161 Thousand SEK | -29.84% |
| 2021 FY | -576 Thousand SEK | -16.36% |
| 2021 Q1 | -124 Thousand SEK | 0.0% |
| 2021 Q4 | -145 Thousand SEK | 0.68% |
| 2021 Q3 | -146 Thousand SEK | 9.32% |
| 2020 Q1 | -11.35 Million SEK | 16.74% |
| 2020 Q2 | -16 Million SEK | -40.95% |
| 2020 FY | -495 Thousand SEK | 98.89% |
| 2020 Q4 | - SEK | 100.0% |
| 2020 Q3 | -19.65 Million SEK | -22.8% |
| 2019 FY | -44.78 Million SEK | -42966.35% |
| 2019 Q4 | -13.63 Million SEK | -11.88% |
| 2019 Q3 | -12.18 Million SEK | -32.97% |
| 2019 Q2 | -9.16 Million SEK | 6.41% |
| 2019 Q1 | -9.79 Million SEK | 0.0% |
| 2018 Q1 | -8.99 Million SEK | -1117.79% |
| 2018 FY | -104 Thousand SEK | -111.88% |
| 2018 Q4 | - SEK | 100.0% |
| 2018 Q3 | -5.73 Million SEK | 15.74% |
| 2018 Q2 | -6.81 Million SEK | 24.25% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | 883.38 Thousand SEK | 0.0% |
| 2017 FY | 875.38 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | 107.221% |
| BioGaia AB (publ) | 950.19 Million SEK | 100.05% |
| Enzymatica AB (publ) | 31.86 Million SEK | 101.494% |
| Enorama Pharma AB (publ) | -3.9 Million SEK | 87.798% |
| Gabather AB (publ) | - SEK | Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | -5188.889% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | 77.323% |
| Nanexa AB (publ) | 59.15 Million SEK | 100.805% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 102.969% |
| ODI Pharma AB | -1.34 Million SEK | 64.521% |
| Orexo AB (publ) | 549.9 Million SEK | 100.087% |
| Probi AB (publ) | 220.21 Million SEK | 100.216% |
| Swedencare AB (publ) | 164.8 Million SEK | 100.289% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.003% |
| Toleranzia AB | -919 Thousand SEK | 48.205% |
| Vivesto AB | -10.65 Million SEK | 95.533% |